Newly diagnosed, histologically confirmed, unresectable stage III NSCLC patients, amenable to receive standard of care chemoradiotherapy with or without durvalumab maintenance, will be enrolled in this study. Whole blood collection will be conducted during the treatment for ctDNA detection in specific time-points of interest. Next-generation sequencing using commercially available panels, and analysis of ctDNA aberrant methylation will be performed. Results will be correlated to patients' recurrence times and survival outcomes.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with newly diagnosed, histologically confirmed, unresectable locally advanced NSCLC.
≥18 years of age.
Ability to understand the written informed consent and willingness to sign it.
You may not be if
Patients who are unwilling to follow-up evaluation of response to therapy.
Any condition that, in the opinion of the investigator, would interfere with study results.